首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
【24h】

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.

机译:异基因干细胞移植的低强度制备​​方案可延迟急性移植物抗宿主病,但不能改善晚期血液系统恶性肿瘤的预后。

获取原文
获取原文并翻译 | 示例
       

摘要

Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to patients who cannot tolerate fully myeloablative regimens. However, relapse and graft-versus-host disease (GVHD) continue to be major causes of morbidity and mortality. We prospectively tested whether a moderate reduction of the intensity of the preparative regimen would lead to significant reduction in regimen-related toxicity without compromising tumor control in a cohort of 44 patients ineligible for conventional hematopoietic stem cell transplantation. Patients were conditioned with fludarabine, busulfan, mycophenolate, and total lymphoid irradiation. Tacrolimus and methotrexate were given as prophylaxis for GVHD. Donors were 5 of 6 or 6 of 6 matched family members. The median age was 61 years. Eleven patients had comorbid conditions that precluded conventional myeloablative transplantation. Fatal regimen-related organ toxicity occurred in 3 patients. The cumulative incidence of grade 2 to 4 or grade 3 to 4 acute GVHD by day 100 was 38% (95% confidence interval [CI] = 25%, 55%) and 20% (95% CI = 10%, 39%), respectively, with a median time to onset of 66 days. For the entire cohort, 1-year overall survival, disease-free survival, and relapse rates were 54% (95% CI = 41%, 71%), 47% (95% CI = 35%, 65%), and 37% (95% CI = 19%, 51%), respectively. Outcomes differed based on stage of disease at time of transplantation, advanced (n = 19) versus nonadvanced (n = 25). Median survival times were 138 days and 685 days for subjects with advanced and nonadvanced disease, respectively (P =.005). After adjusting for age and comorbidity, disease stage continued to be significantly associated with overall survival (P =.005). In conclusion, a moderate reduction in conditioning dose intensity resulted in delayed onset of acute GVHD (compared with historical controls). A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control.
机译:降低的调节强度将同种异体造血干细胞移植的选择范围扩展到了不能完全接受清髓疗法的患者。然而,复发和移植物抗宿主病(GVHD)仍然是发病率和死亡率的主要原因。我们前瞻性地测试了在不适合常规造血干细胞移植的44名患者中,适度降低制备方案的强度是否会导致方案相关毒性的显着降低而不损害肿瘤控制。患者接受氟达拉滨,白消安,霉酚酸酯和总淋巴样照射的治疗。给予他克莫司和甲氨蝶呤预防GVHD。捐助者是6个中的5个或6个匹配的家庭成员中的6个。中位年龄为61岁。 11例患者患有合并疾病,无法进行常规的清髓性移植。与致命方案相关的器官毒性发生在3例患者中。到第100天,2至4级或3至4级急性GVHD的累积发生率分别为38%(95%置信区间[CI] = 25%,55%)和20%(95%CI = 10%,39%) ,平均起病时间为66天。对于整个队列,1年总生存期,无病生存期和复发率分别为54%(95%CI = 41%,71%),47%(95%CI = 35%,65%)和37百分比(95%CI = 19%,51%)。结果因移植时的疾病阶段而异,晚期(n = 19)与非晚期(n = 25)。患有晚期和非晚期疾病的受试者的中位生存时间分别为138天和685天(P = .005)。在调整年龄和合并症后,疾病阶段继续与总体生存率显着相关(P = .005)。总之,调节剂量强度的适度降低导致急性GVHD的发作延迟(与历史对照相比)。调节强度的降低与晚期疾病患者的不良生存相关,这突出了调节方案对肿瘤控制的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号